4 hrs ago
Amrutanjan and Jagsonpal Offer Contrasting Cash-Return Investment Cases
Amrutanjan Health Care and Jagsonpal Pharmaceuticals are two Indian drug companies being considered for an investment watchlist.
Both earn strong returns from the money used in their businesses and have very little debt.
Amrutanjan is building a large factory to make sanitary napkins itself.
However, its main pain-relief business has barely grown, and recent profits dropped sharply.
Jagsonpal has improved its profit margins and has a large amount of cash.
It also bought most of a company called Aequitas Healthcare to gain access to hospitals.
Aequitas is currently only slightly profitable, so the purchase still needs to succeed.
Both companies pay dividends, but Jagsonpal’s recent yield includes a special payment.
The article says investors should watch both companies rather than treat the analysis as a recommendation.
Amrutanjan Health Care has a 25% FY26 ROCE, minimal debt and a 1% dividend yield.
Amrutanjan commissioned a Rs 150 crore sanitary-napkin plant, but its June-quarter profit fell 47.7%.
Jagsonpal Pharmaceuticals reported 23% FY26 ROCE, Rs 191 crore in free cash and a 1.7% dividend yield.
Jagsonpal’s margins improved sharply, while its Rs 20.8 crore Aequitas acquisition remains dependent on future execution.
Both companies trade at about 23 times earnings, but investors must assess plant utilization, growth and acquisition risks.
- Who
- Amrutanjan Health Care and Jagsonpal Pharmaceuticals, two Indian pharmaceutical companies.
- What
- The article compares their financial performance, dividend policies, capital allocation and business risks.
- Where
- India; Amrutanjan’s new plant is in Rangareddy district, Telangana, while Jagsonpal is based in Gurugram.
- When
- The comparison uses FY26 results and events reported through September 2026.
- Why
- Both companies passed a screen for strong capital returns, relatively high dividends and negligible debt, but have different growth and cash-use strategies.
Amrutanjan Value and Capacity Bet
Jagsonpal Margin and Acquisition Bet
Current investment appeal
Amrutanjan Value and Capacity Bet
Amrutanjan trades at about 23 times earnings, below the stated industry median of 35 times, and has a decade-long record of strong capital returns.
Jagsonpal Margin and Acquisition Bet
Jagsonpal also trades at about 23 times earnings, but its appeal is stronger recent operating momentum, including higher margins and June-quarter profit growth.
Use of cash
Amrutanjan Value and Capacity Bet
Amrutanjan is investing Rs 150 crore in in-house sanitary-napkin manufacturing to gain more control over the Comfy business.
Jagsonpal Margin and Acquisition Bet
Jagsonpal returned cash through a buyback and dividend, while also spending Rs 20.8 crore to acquire access to a hospital distribution channel.
Main risk
Amrutanjan Value and Capacity Bet
The new plant must reach adequate utilization, while the core pain-management business has shown weak growth and recent margin pressure.
Jagsonpal Margin and Acquisition Bet
Aequitas Healthcare is barely profitable, and Jagsonpal’s recent dividend included a special component that may not recur.
Key facts
- Amrutanjan market capitalization
- Rs 1,419 crore
- Jagsonpal market capitalization
- Rs 1,536 crore
- Amrutanjan FY26 ROCE
- 25%; borrowings were Rs 2 crore
- Jagsonpal FY26 ROCE
- 23%; borrowings were Rs 8 crore and free cash was Rs 191 crore
- Amrutanjan expansion
- A Rs 150 crore sanitary-napkin plant with annual capacity of 700 million napkins
- Jagsonpal dividend
- Rs 4 per share, producing a stated yield of 1.7%; the payment included a special component
- Jagsonpal acquisition
- An 85% stake in Aequitas Healthcare acquired for about Rs 20.8 crore




